This invention provides for the prevention and treatment of tumor growth, metastasis,
and cancer-mediated thrombosis through the administration, in combination, of a
short or long acting GPIIb/IIIa antagonist (A) and anticoagulant (B) that might
include the following: UFH or low molecular weight heparin, (LMWH), ultra LMWH,
pentasaccharide or direct anti-Xa or direct anti-IX/IXa, direct anti-IIa (thrombin)
or tissue factor pathway inhibitor (TFPI) by any means that produces contact of
the agents with their site of action wherein at least one of the components of
each of these combinations is given in reduced amount. This combined formulation
could be used as a stand-alone regimen or in conjunction with other therapies (chemotherapy,
radiotherapy, angiogenesis inhibitors, . . . ), and pre- & post-tumor surgery in
the prevention and treatment of cancer associated metastasis, angiogenesis, tumor
growth, and thrombosis.
